Clinical Trial Detail

NCT ID NCT03915405
Title KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Kyowa Kirin Pharmaceutical Development, Inc.
Indications

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

urethra transitional cell carcinoma

transitional cell carcinoma

Therapies

Avelumab + KHK2455

Age Groups: adult senior

No variant requirements are available.